Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates
Key Terms
kras g12d medical
pdac medical
nsclc medical
overall response rate medical
disease control rate medical
pdufa regulatory
breakthrough therapy designation regulatory
AVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of
Based on FDA guidance, Company to develop Phase 2 registration-directed protocols to evaluate VS-7375, a highly selective, oral KRAS G12D (ON/OFF) inhibitor with best-in-class potential, in 2L PDAC, 2L/3L NSCLC and 2L+ CRC in combination with cetuximab
Cleared multiple dose levels of VS-7375 with no DLTs, continuing dose escalation to 1200 mg QD; cleared 600 mg QD dose level of VS-7375 in combination with cetuximab with no DLTs; continuing higher dose evaluations
Company cash, cash equivalents, and investments of
“2025 was a transformative year for us, highlighted by the landmark FDA approval of AVMAPKI FAKZYNJA CO-PACK, the only medicine approved to specifically treat KRAS-mutated recurrent LGSOC. The launch is off to a strong start, and this novel-novel combination therapy is gaining positive response across the LGSOC community with gynecologic and medical oncologists in both academic and community settings increasingly turning to it when patients experience a first or subsequent recurrence. We also made considerable progress with VS-7375, our oral, KRAS G12D (ON/OFF) inhibitor with best-in-class potential for solid tumor cancers, clearing multiple dose levels across both monotherapy and cetuximab combination cohorts with no DLTs or major toxicities. Building on the insights from the
Fourth Quarter 2025 and Recent Highlights
AVMAPKI™ FAKZYNJA™ CO-PACK (avutometinib capsules; defactinib tablets)
-
AVMAPKI FAKZYNJA CO-PACK generated net product revenues of
$17.5 million $30.9 million U.S. Food and Drug Administration (FDA) approval in May 2025, approximately two months ahead of its Prescription Drug User Fee Act (PDUFA) action date of June 30, 2025. -
On February 4, 2026, the Company announced updated data for RAMP 201J in
Japan with a data cutoff of January 30, 2026. Of the 16 patients enrolled with a median follow-up of 10 months, a confirmed overall response rate (ORR) of38% (6/16) was achieved by investigator assessment. Among patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), the confirmed ORR was57% (4/7) and the disease control rate (DCR) was100% (7/7). Among patients with KRAS wild-type recurrent LGSOC, the confirmed ORR was22% (2/9) and the DCR was89% (8/9). Of the 16 patients enrolled, 11 patients remain on treatment. No patients discontinued due to an adverse event. The safety profile was similar to previously reported data outside ofJapan . Steady-state exposures of avutometinib and defactinib in the RAMP 201J study were comparable to those seen in RAMP 201. -
On February 25, 2026, the annual update of the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ovarian Cancer was released. The Guidelines did not expand the recommendation for avutometinib plus defactinib to include patients with recurrent LGSOC without a KRAS mutation. The Guidelines retained the category 2A recommendation for avutometinib plus defactinib for patients with KRAS-mutated recurrent LGSOC.
“We are disappointed for the patients with KRAS wild-type recurrent LGSOC, who currently have no targeted, FDA-approved treatment options specifically for their disease and face a particularly poor prognosis. Across three separate clinical trials (the FRAME study, RAMP 201, and RAMP 201J) we have observed what we believe are robust objective responses rates for patients with recurrent LGSOC with and without KRAS mutations. We remain committed to advancing the clinical evidence through longer term follow-up analyses from the RAMP 201 study planned for the SGO annual meeting, and completing our ongoing confirmatory RAMP 301 Phase 3 clinical trial, which includes patients with and without KRAS mutations, and look forward to sharing these data with the NCCN and the medical community to support future guideline consideration,” said John Hayslip, chief medical officer at Verastem Oncology.
Expected Key Milestones:
-
Maximize adoption of AVMAPKI FAKZYNJA CO-PACK in the
U.S. as the treatment of choice at the earliest recurrence, leveraging its robust clinical data. - Report a topline readout of the primary endpoint in the RAMP 301 trial in mid-2027.
-
Continue to pursue regulatory paths for potential expansion into
Europe andJapan .
VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor in Advanced Solid Tumors
-
The Company today announced an update on its progress with the VS-7375-101 Phase 1/2 study:
- After clearing the 900 mg daily (QD) dose level with no dose-limiting toxicities (DLTs), the dose escalation phase will continue to 1200 mg QD to further interrogate the dose range and characterize the safety, tolerability, and efficacy profile of VS-7375.
- The 600 mg QD dose level of VS-7375 in combination with cetuximab was cleared with no DLTs and higher doses are now being evaluated.
-
In a pharmacokinetics (PK) analysis, doses of VS-7375 at 600 mg QD and above, with feeding and anti-emetic prophylaxis, yielded similar exposures to fasted patients in
China . The exposures achieved cover the exposures in preclinical models necessary for maximal anti-tumor efficacy. -
As of the January 30, 2026 data cutoff, VS-7375 demonstrated an encouraging safety profile and was generally well-tolerated across all monotherapy dose levels evaluated to date. Patients (n=23) receiving VS-7375 at either 400 mg QD, 600 mg QD or 900 mg QD with a mean duration of therapy of 1.6 months (0.7-5.6), reported no drug related liver function test abnormalities. There was no drug-related neutropenia greater than Grade 2 and rates of nausea, vomiting and diarrhea remained lower than those reported by the Company’s partner in
China . No DLTs have been reported to date, and the maximum tolerated dose has not been reached. - Following recent feedback from the FDA, the Company is amending the VS-7375-101 Phase 1/2 protocol to separate out disease-specific Phase 2 registration-directed trials for KRAS G12D mutated 2L pancreatic ductal adenocarcinoma (PDAC) and 2L/3L non-small cell lung cancer (NSCLC) (monotherapy) and 2L+ colorectal cancer (CRC) in combination with cetuximab.
- In January 2026, the Company reported updates on its VS-7375-101 trial including that it had cleared the 400 mg QD, 600 mg QD and 900 mg QD dose levels with no DLTs and no major toxicities. The VS-7375 monotherapy expansion cohorts were initiated, and the cohort sizes were expanded in 2L PDAC, 2L/3L NSCLC, and 2L+ other KRAS G12D-mutated solid tumors. In the VS-7375 dose-escalation combination cohort, the 400 mg QD dose was cleared in combination with cetuximab with no DLTs. The combination dose escalation cohorts were initiated in 1L NSCLC and 2L PDAC at the end of 2025.
-
In October 2025, the Company announced a preliminary update on the Phase 1/2 monotherapy dose escalation trial of VS-7375 in patients with previously treated advanced KRAS G12D mutant solid tumors. In the study, VS-7375 cleared both the 400 mg QD and the 600 mg QD monotherapy doses with no DLTs observed. At the two dose levels evaluated in the
U.S. cohort, no nausea, vomiting, or diarrhea greater than Grade 1 were reported. In addition, no new safety signals have been observed relative to earlier data presentations in both PDAC and NSCLC by GenFleet Therapeutics, the Company’s partner inChina . Of the five efficacy evaluable patients in the VS-7375-101 study with at least one scan, four out of five patients have had a tumor reduction and were still on treatment.
The Company shared multiple updates from GenFleet and its ongoing evaluation of VS-7375, known as GFH375, in
-
On March 2, 2026, GenFleet announced that GFH375 was granted its first Breakthrough Therapy Designation in
China for patients with KRAS G12D-mutated NSCLC who have received prior systemic therapy. -
In December 2025, GenFleet announced the initiation of a registrational Phase 3 study for GFH375 in patients with pretreated KRAS G12D-mutated metastatic pancreatic cancer in
China . -
In October 2025, the Company announced updated data for GFH375 in PDAC featured in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress. GenFleet shared additional analyses of this data set on October 27, 2025:
-
In a subgroup analysis, 12 patients with 2L PDAC at 600 mg QD achieved an ORR of
58.3% and a DCR of100% . In the 3L+ setting, 47 PDAC patients receiving 600 mg QD achieved an ORR of36.2% and a DCR of95.7% . In the 2L subgroup, the median progression free survival (mPFS) and median overall survival (mOS) have not been reached. An additional analysis of gastrointestinal disorders, hematological toxicities, and liver enzyme abnormalities in 2L+ patients with PDAC (n=66) at 600 mg QD showed no adverse events Grade ≥3 occurred at rates above8.0% . -
In an analysis of pre-treated patients with NSCLC at 600 mg QD, the four-month PFS rate was greater than
75% and the mPFS has not been reached. The median follow-up time was 4.2 months.
-
In a subgroup analysis, 12 patients with 2L PDAC at 600 mg QD achieved an ORR of
-
In October 2025, GenFleet announced that the first patient has been dosed in a Phase 1b/2 study of GFH375 combined with cetuximab or chemotherapy for advanced solid tumors, including 1L PDAC, in
China . -
In August 2025, the Company announced data of GFH375 would be featured in a mini oral presentation at the IASLC 2025 World Conference on Lung Cancer (WCLC) on September 8, 2025. At the recommended Phase 2 dose (RP2D) of 600 mg QD, the ORR was
68.8% (11/16) (both confirmed and unconfirmed) and the DCR was93.8% (15/16). Among the 26 evaluable patients with NSCLC treated across all dose levels, the ORR was57.7% (15/26) (both confirmed and unconfirmed) and the DCR was88.5% (23/26).
Expected Key Milestones:
- Report early data from the VS-7375-101 trial in 1H 2026.
- Select the RP2D with cetuximab and initiate the CRC combination expansion cohort in 1H 2026.
- Complete enrollment in combination dose-escalation cohorts in mid-2026.
- Complete enrollment in monotherapy expansion cohorts in 2H 2026.
- Select the RP2D and plan to initiate the PDAC and NSCLC combination expansion cohorts in 2H 2026.
RAMP 205: Avutometinib Plus Defactinib in Combination with Chemotherapy in 1L Metastatic Pancreatic Cancer
- In November 2025, the Company announced that enrollment was completed in the expansion cohort in Q3 2025.
Expected Key Milestone:
- Report an update on the safety and efficacy of the RAMP 205 expansion cohort with at least six months of follow-up on all patients in Q2 2026.
Upcoming Presentations
-
Multiple abstracts were selected for oral and poster presentations at the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting on Women’s Cancer on April 10-13 in
Puerto Rico . These presentations will include a late-breaking oral presentation on the long-term analysis of the Phase 2 RAMP 201 trial of avutometinib and defactinib combination in recurrent LGSOC.
Corporate Updates
- In December 2025, the Company announced John Johnson, current board member, was appointed to chairman of Verastem’s Board of Directors, and Michael Kauffman, M.D., Ph.D., lead director since 2016, was appointed to president of development of Verastem.
-
In November 2025, the Company announced it had completed a public offering of over
$96.9 million
Fourth Quarter 2025 Financial Results
Verastem Oncology ended the fourth quarter of 2025 with cash, cash equivalents, and investments of
Net product revenue for the three months ended December 31, 2025 (the “2025 Quarter”) was
Total operating expenses for the 2025 Quarter were
Research & development expenses for the 2025 Quarter were
Selling, general & administrative expenses for the 2025 Quarter were
Net loss (GAAP basis) for the 2025 Quarter was
For the 2025 Quarter, non-GAAP adjusted net loss was
Full-Year 2025 Financial Results
Net product revenue for the year ended December 31, 2025 (the “2025 Period”) was
Total operating expenses for the 2025 Period were
Research & development expenses for the 2025 Period were
Selling, general & administrative expenses for the 2025 Period were
Net loss for the 2025 Period was
For the 2025 Period, non-GAAP adjusted net loss was
Conference Call and Webcast
Verastem will host a conference call and webcast today at 4:30 p.m. ET to review the fourth quarter and full year 2025 financial results and recent business updates. To access the conference call, please dial (888) 596-4144 (
Use of Non-GAAP Financial Measures
To supplement Verastem Oncology’s condensed consolidated financial statements, which are prepared and presented in accordance with generally accepted accounting principles in
Management believes this non-GAAP information is useful for investors, taken in conjunction with the Company’s GAAP financial statements, because it provides greater transparency and period-over- period comparability with respect to the Company’s operating performance and can enhance investors’ ability to identify operating trends in the Company’s business. Management uses these measures, among other factors, to assess and analyze operational results and trends and to make financial and operational decisions. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the Company’s operating results as reported under GAAP, not in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP. In addition, these non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. The determination of the amounts that are excluded from non-GAAP financial measures is a matter of management judgment and depends upon, among other factors, the nature of the underlying expense or income amounts. Reconciliations between these non-GAAP financial measures and the most comparable GAAP financial measures for the three months and year ended December 31, 2025, and 2024 are included in the tables accompanying this press release after the unaudited condensed consolidated financial statements.
About AVMAPKI and FAKZYNJA Combination Therapy
AVMAPKI (avutometinib) inhibits MEK kinase activity while also blocking the compensatory reactivation of MEK by upstream RAF. RAF and MEK proteins are regulators of the RAS/RAF/MEK/ERK (MAPK) pathway. Blocking RAF and/or MEK activates FAK, a key mediator of drug resistance. FAKZYNJA (defactinib) is a FAK inhibitor and together, the avutometinib and defactinib combination was designed to provide a more complete blockade of the signaling that drives the growth and drug resistance of RAS/MAPK pathway-dependent tumors.
The
AVMAPKI FAKZYNJA CO-PACK
Indication
AVMAPKI FAKZYNJA CO-PACK is indicated for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Important Safety Information
Warnings and Precautions
- Ocular Toxicities: Ocular toxicities, including visual impairment and vitreoretinal disorders, occurred. Perform comprehensive ophthalmic evaluation at baseline, prior to cycle 2, every three cycles thereafter, and as clinically indicated. Withhold AVMAPKI FAKZYNJA CO-PACK for ocular toxicities until improvement at the same or reduced dose. Permanently discontinue AVMAPKI FAKZYNJA CO-PACK for any grade 4 toxicity.
- Serious Skin Toxicities: Skin toxicities, including photosensitivity and severe cutaneous adverse reactions (SCARSs) occurred. Adhere to concomitant medications. Monitor for skin toxicities and interrupt, reduce or permanently discontinue AVMAPKI FAKZYNJA CO-PACK based on severity, tolerability and duration.
- Hepatotoxicity: Monitor liver function tests prior to each cycle, on day 15 of the first 4 cycles, and as clinically indicated. Withhold, reduce or discontinue AVMAPKI FAKZYNJA CO-PACK based on severity and persistence of abnormality.
- Rhabdomyolysis: Monitor creatine phosphokinase prior to the start of each cycle, on day 15 of the first four cycles, and as clinically indicated. If increased CPK occurs, evaluate patients for rhabdomyolysis or other causes. Withhold, reduce or permanently discontinue AVMAPKI FAKZYNJA CO-PACK based on severity and duration of the adverse reaction.
- Embryo-Fetal Toxicity: AVMAPKI FAKZYNJA CO-PACK can cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception.
Adverse Reactions
The most common (≥
Drug Interactions
- Strong and moderate CYP3A4 inhibitors: Avoid concomitant use with AVMAPKI FAKZYNJA CO-PACK.
- Strong and moderate CYP3A4 inducers: Avoid concomitant use with AVMAPKI FAKZYNJA CO-PACK.
- Warfarin: Avoid concomitant use of AVMAPKI FAKZYNJA CO-PACK with warfarin and use an alternative to warfarin.
- Gastric acid reducing agents: Avoid concomitant use of AVMAPKI FAKZYNJA CO-PACK with proton pump inhibitors (PPIs) or H2 receptor antagonists. If use of an acid-reducing agent cannot be avoided, administer FAKZYNJA 2 hours before or 2 hours after the administration of a locally acting antacid.
Use in Specific Populations
- Lactation: Advise not to breastfeed.
- Fertility: May impair fertility in males and females.
Click here for full Prescribing Information.
About VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor
VS-7375 is a potential best-in-class, potent, and selective oral KRAS G12D dual ON/OFF inhibitor. VS-7375 is the lead program from the Verastem Oncology discovery and development collaboration with GenFleet Therapeutics. Verastem initiated VS-7375-101, an international Phase 1/2 clinical trial, in June of 2025 in the
About the GenFleet Therapeutics Collaboration
The collaboration with GenFleet Therapeutics aims to advance three oncology discovery programs related to RAS/MAPK pathway-driven cancers. The collaboration provides Verastem with an exclusive option to obtain a license for each of the three compounds in the collaboration after the successful completion of pre-determined milestones in a Phase 1 trial. Verastem selected VS-7375 (also known as GFH375), an oral KRAS G12D (ON/OFF) inhibitor, as its lead program in December 2023 and the license for VS-7375 that was exercised in January 2025 is the first one from this collaboration. The licenses would give Verastem development and commercialization rights outside the GenFleet markets of mainland
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI™ FAKZYNJA™ CO-PACK in the
Forward-Looking Statements
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning. Such forward-looking statements address various matters about, among other things, Verastem Oncology’s programs and product candidates, strategy, future plans and prospects, including statements related to the potential for and timing of commercialization of product candidates, the anticipated timing for the IND application for VS-7375/GFH375, the expected outcome and benefits of the Company’s collaboration with GenFleet Therapeutics (
Verastem Oncology Condensed Consolidated Balance Sheets (in thousands) |
|||||
December 31, 2025 |
December 31, 2024 |
||||
Cash, cash equivalents, & investments |
$ |
204,990 |
$ |
88,818 |
|
Accounts receivable, net |
|
8,813 |
|
|
— |
Inventory |
|
1,833 |
|
|
— |
Grants receivable |
200 |
200 |
|||
Prepaid expenses and other current assets |
7,577 |
5,943 |
|||
Property and equipment, net |
— |
32 |
|||
Right-of-use asset, net |
491 |
1,405 |
|||
Intangible assets, net |
|
16,426 |
|
|
— |
Restricted cash and other assets |
6,112 |
5,140 |
|||
Total assets |
$ |
246,442 |
$ |
101,538 |
|
Current Liabilities |
72,268 |
30,973 |
|||
Long term debt |
76,330 |
40,724 |
|||
Vendor financing arrangement, long-term |
|
5,000 |
|
|
— |
Lease liability, long-term |
|
— |
|
|
535 |
Warrant Liability |
35,647 |
58,199 |
|||
Stockholders’ equity |
57,197 |
(28,893) |
|||
Total liabilities, convertible preferred stock and stockholders’ equity |
$ |
246,442 |
$ |
101,538 |
|
Verastem Oncology Condensed Consolidated Statements of Operations (in thousands, except per share amounts) (unaudited) |
|||||||||||
Three months ended December 31, |
Year ended December 31, |
||||||||||
2025 |
2024 |
2025 |
2024 |
||||||||
Revenue: |
|||||||||||
Product Revenue, net |
$ |
17,535 |
$ |
— |
$ |
30,914 |
$ |
— |
|||
Sale of COPIKTRA license and related assets |
— |
— |
— |
10,000 |
|||||||
Total revenue |
|
17,535 |
|
— |
|
30,914 |
|
10,000 |
|||
Operating expenses: |
|||||||||||
Cost of sales – product |
|
2,611 |
|
— |
|
4,600 |
|
— |
|||
Cost of sales – intangible amortization |
|
280 |
|
— |
|
698 |
|
— |
|||
Research and development |
31,675 |
20,811 |
114,599 |
81,334 |
|||||||
Selling, general and administrative |
|
24,443 |
|
10,779 |
|
81,146 |
|
43,622 |
|||
Total operating expenses |
|
59,009 |
|
31,590 |
|
201,043 |
|
124,956 |
|||
Loss from operations |
|
(41,474) |
|
(31,590) |
|
(170,129) |
|
(114,956) |
|||
Other income (expense) |
(18) |
9 |
(203) |
(123) |
|||||||
Interest income |
|
1,103 |
|
968 |
|
4,068 |
|
4,149 |
|||
Interest expense |
|
(415) |
|
(1,146) |
|
(1,138) |
|
(4,562) |
|||
Loss on debt extinguishment |
|
— |
|
— |
|
(1,826) |
|
— |
|||
Change in fair value of preferred stock tranche liability |
— |
— |
|
— |
4,189 |
||||||
Change in fair value of warrant liability |
10,485 |
(32,606) |
(27,492) |
(19,149) |
|||||||
Change in fair value of Notes |
|
(2,597) |
|
— |
|
(12,751) |
|
— |
|||
Net loss before taxes |
(32,916) |
(64,365) |
(209,471) |
(130,452) |
|||||||
Income tax expense |
— |
(185) |
— |
(185) |
|||||||
Net Loss |
$ |
(32,916) |
$ |
(64,550) |
$ |
(209,471) |
$ |
(130,637) |
|||
Net loss per share—basic |
$ |
(0.39) |
$ |
(1.33) |
$ |
(3.02) |
$ |
(3.66) |
|||
Net loss per share—diluted |
$ |
(0.50) |
$ |
(1.33) |
$ |
(3.02) |
$ |
(3.66) |
|||
Weighted average common shares outstanding used in computing: |
|
|
|
|
|||||||
Net loss per share – basic |
83,400 |
48,709 |
69,309 |
35,713 |
|||||||
Net loss per share – diluted |
|
86,710 |
|
48,709 |
|
69,309 |
|
35,713 |
|||
Verastem Oncology Reconciliation of GAAP to Non-GAAP Financial Information (in thousands, except per share amounts) (unaudited) |
|||||||||||
Three months ended December 31, |
Year ended December 31, |
||||||||||
2025 |
2024 |
2025 |
2024 |
||||||||
Net loss reconciliation: |
|||||||||||
Net loss (GAAP basis) |
$ |
(32,916) |
$ |
(64,550) |
$ |
(209,471) |
$ |
(130,637) |
|||
Adjust: |
|
||||||||||
Stock-based compensation expense |
|
2,025 |
|
2,019 |
|
9,404 |
|
7,342 |
|||
Amortization of acquired intangible assets |
|
280 |
— |
698 |
— |
||||||
Non-cash interest, net |
|
— |
|
207 |
|
29 |
|
(5) |
|||
Change in fair value of preferred stock tranche liability |
|
— |
|
— |
|
— |
|
(4,189) |
|||
Change in fair value of warrant liability |
|
(10,485) |
32,606 |
27,492 |
19,149 |
||||||
Non-cash change in fair value of Notes |
|
890 |
|
— |
|
6,560 |
|
— |
|||
Loss on debt extinguishment |
|
— |
|
— |
|
1,826 |
|
— |
|||
Severance and other |
|
392 |
|
371 |
|
392 |
|
990 |
|||
Adjusted net loss (non-GAAP basis) |
$ |
(39,814) |
$ |
(29,347) |
$ |
(163,070) |
$ |
(107,350) |
|||
|
|
|
|
|
|
|
|
|
|||
Reconciliation of net loss per share |
|
|
|
|
|
|
|
|
|||
Net loss per share – basic (GAAP basis) |
|
(0.39) |
$ |
(1.33) |
$ |
(3.02) |
$ |
(3.66) |
|||
Adjust per basic share |
|
|
|
|
|
|
|
|
|||
Stock-based compensation expense |
|
0.02 |
|
0.04 |
|
0.14 |
|
0.21 |
|||
Amortization of acquired intangible assets |
|
— |
|
— |
|
0.01 |
|
— |
|||
Non-cash interest, net |
|
— |
|
0.01 |
|
— |
|
— |
|||
Change in fair value of preferred stock tranche liability |
|
— |
|
— |
|
— |
|
(0.12) |
|||
Change in fair value of warrant liability |
|
(0.12) |
|
0.67 |
|
0.39 |
|
0.53 |
|||
Non-cash change in fair value of Notes |
|
0.01 |
|
— |
|
0.09 |
|
— |
|||
Loss on debt extinguishment |
|
— |
|
— |
|
0.03 |
|
— |
|||
Severance and other |
|
— |
|
0.01 |
|
0.01 |
|
0.03 |
|||
Adjusted net loss per share – basic (non-GAAP basis) |
$ |
(0.48) |
$ |
(0.60) |
$ |
(2.35) |
$ |
(3.01) |
|||
Weighted average common shares outstanding used in computing net loss per share—basic |
|
83,400 |
|
48,709 |
|
69,309 |
|
35,713 |
|||
View source version on businesswire.com: https://www.businesswire.com/news/home/20260304011595/en/
For Investor and Media Inquiries:
Julissa Viana
Vice President, Corporate Communications,
Investor Relations & Patient Advocacy
investors@verastem.com or
media@verastem.com
Source: Verastem Oncology
